Suppr超能文献

工程化间充质干细胞衍生的细胞外囊泡:杀伤肿瘤并保护器官。

Engineered mesenchymal stem cell-derived extracellular vesicles: kill tumors and protect organs.

机构信息

Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.

Stem Cell and Regeneration Medicine Institute, Research Center of Translational Medicine, Naval Medical University, Shanghai, 200433, China.

出版信息

Theranostics. 2024 Sep 23;14(16):6202-6217. doi: 10.7150/thno.99618. eCollection 2024.

Abstract

Solid tumors cause 90% of cancers and remain the primary cause of mortality. However, treating solid tumors presents significant challenges due to the complex tumor microenvironment and drug resistance, leading to inadequate treatment targeting and severe side effects. Surgery, radiotherapy, and chemotherapy Although it is an effective method for the treatment of solid tumors, it can lead to organ dysfunction and affect patient prognosis. Therefore, it is imperative to improve treatment precision and organ repair capabilities to manage solid tumors. Mesenchymal stem cell extracellular vesicles (MSC-EVs) have wide application prospects as a new agent for solid tumor therapy. Firstly, MSC-EVs is a derivative of MSCs. It has the function of promoting tissue regeneration by inducing dedifferentiation in surviving cells after injury. Additionally, MSC-EVs offer unique advantages in terms of safety, stability and penetrability, making them a promising extracellular therapeutic modality for solid tumor treatment. Finally, MSC-EVs are able to enhance therapeutic efficacy through engineering strategies. To sum up, this review takes MSC-EVs as its object. And then we discuss recent advancements and engineering strategies in the use of MSC-EVs for soid tumor suppression. This review aims to inspire researchers to devise a new method for effectively treat solid tumors.

摘要

实体瘤导致 90%的癌症,仍是主要的死亡原因。然而,由于肿瘤微环境复杂和药物耐药性,实体瘤的治疗仍然具有很大的挑战性,导致靶向治疗不足和严重的副作用。手术、放疗和化疗虽然是治疗实体瘤的有效方法,但会导致器官功能障碍和影响患者预后。因此,提高治疗精度和器官修复能力来治疗实体瘤迫在眉睫。间充质干细胞外泌体 (MSC-EVs) 作为一种治疗实体瘤的新药物具有广泛的应用前景。首先,MSC-EVs 是 MSC 的衍生物,它通过诱导损伤后存活细胞的去分化,具有促进组织再生的功能。此外,MSC-EVs 在安全性、稳定性和穿透性方面具有独特的优势,使其成为治疗实体瘤的一种有前途的细胞外治疗方式。最后,MSC-EVs 可以通过工程策略来提高治疗效果。总之,本综述以 MSC-EVs 为对象,讨论了 MSC-EVs 用于抑制实体瘤的最新进展和工程策略。本综述旨在启发研究人员设计一种有效治疗实体瘤的新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bf8/11488101/ca916d01ab55/thnov14p6202g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验